Company intelligence / Profile preview

Abrexa Pharmaceuticals

San Diego, California, United Stateskando.tech ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Abrexa Pharmaceuticals is developing J147, an oral small molecule derived from curcumin, targeting neurodegenerative diseases. A completed Phase I trial demonstrated safety and tolerability in healthy volunteers. Preclinical data suggest efficacy against acute ischemic stroke and potential benefits in aging models. The approach differs from traditional amyloid-targeting Alzheimer’s drugs by focusing on anti-aging mechanisms.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Cedars-Sinai Medical Center

Beyond the preview

Go deeper on Abrexa Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abrexa Pharmaceuticals.

Explore the full profile